As the UK’s leading breast cancer charity, it is essential that we engage with key stakeholders that can help people affected by breast cancer to live and live well. The pharmaceutical industry has a crucial role to play in achieving this vision – and collaborating with the industry is something we know our supporters understand and want us to do.
A summary of our guiding principles
-
We are open and transparent about our partnerships with the industry and our pharmaceutical and life sciences policy provides clear guidance on how we work with companies in this sector. This policy is reviewed yearly by the board of trustees.
-
We have no preference for working with any one company, and welcome funding from multiple companies where practical and appropriate.
-
We do not accept pharmaceutical funding or donations for our policy and campaigns work. Where necessary, we will campaign against pharmaceutical companies on issues regarding access to drugs, in the interests of breast cancer patients, regardless of whether Breast Cancer Now is currently receiving funding or has historically received funding from a specific company.
-
We have agreements in place for each partnership and limits on donations as a percentage of our annual income.
Support in the latest financial year
We thank the following companies for providing donations and sponsorship, during our financial year August 2023 – July 2024, that amounted to £311,526
- Exact Sciences UK Ltd
- Gilead Sciences Ltd
- Lilly UK
- Menarini Stemline UK Limited
- MSD
- Novartis Pharmaceuticals UK Limited
- Pierre Fabre Limited
- Roche Products Ltd
- Seagen UK Ltd
Support included donations towards these services
-
Talk to our nurses
Our nurses are here for you. Whether you'd like to give us a call or pop us a message, we're here to help.
-
The Service Pledge
Our Service Pledge focuses on improving breast cancer services. It’s a partnership between patients, healthcare professionals and cancer all...
-
Living with Secondary Breast Cancer groups
You’ll be able to talk, listen and learn with people who understand the challenges that secondary breast cancer brings.
